Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Metclan** is a topical fixed-dose combination of the lincosamide antibiotic clindamycin and the retinoid tretinoin, developed and manufactured by Laboratorios Q Pharma. The company pipeline identifies the product as containing clindamycin 5 mg plus tretinoin 0.15 mg. Clindamycin inhibits bacterial protein synthesis through binding to the bacterial 50S ribosomal subunit, while tretinoin activates retinoic acid receptors to normalize follicular epithelial differentiation and reduce comedone formation. The product is intended for dermatologic use, with acne vulgaris inferred as the relevant indication based on the established use of topical clindamycin-tretinoin combinations. Comparable clindamycin phosphate and tretinoin topical combination products are indicated for acne vulgaris. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f772408-52a3-45b2-b053-8fc78948983c))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + tretinoin (Laboratorios Q Pharma).